Director, BioPharma Business Development

United States

Apply with AI Apply

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Pharmaceuticals, Contract Research OrganizationsIndustries

Requirements

Candidates must possess an advanced degree (PhD, MD, or MBA) in life sciences or a related field, coupled with over 10 years of experience in sales or business development, ideally within the proteomics, diagnostics, or biotech industries. A proven history of closing strategic deals and managing complex partnerships is essential, along with a deep understanding of drug development, clinical trial design, biomarker validation, and regulatory frameworks. The ideal candidate will demonstrate innovative thinking, a customer-centric approach, and excellent communication, negotiation, and leadership skills.

Responsibilities

The Director, BioPharma Business Development will lead strategic partnerships and commercial initiatives within large Pharmaceutical companies, biotech, and Contract Research Organizations to increase adoption and utilization of Alamar’s ultra-sensitive proteomics platform. Key responsibilities include identifying, negotiating, and managing commercial opportunities, developing and executing strategies for market expansion in drug discovery and translational research, and collaborating with R&D, regulatory, and commercial teams. The role also involves building relationships with key opinion leaders, providing input on clinical validation strategies and regulatory pathways, and driving revenue growth through commercial partnerships and strategic deals.

Skills

Business Development

Strategic Partnerships

Commercial Initiatives

Proteomics

Biomarker Discovery

Drug Development

Regulatory Landscape

Sales

Negotiation

Customer Engagement

Clinical Research

FDA

Alamar Biosciences

Develops technology for protein detection and measurement

About Alamar Biosciences

Alamar Biosciences focuses on the study of proteins, known as proteomics, to enhance disease detection and treatment. The company has created NULISA™, a technology that can detect and measure proteins in the human body with high sensitivity and a wide range. This allows researchers and clinicians to profile clinically relevant protein biomarkers, which are essential for developing new diagnostic tests and treatments for various diseases. Alamar's ARGO™ system complements NULISA™ by providing a fully automated, high-throughput platform for precision proteomics. Unlike competitors, Alamar's technology simplifies the process, reducing the need for extensive technical expertise, making it more accessible to clients. The goal of Alamar Biosciences is to improve our understanding of proteins in health and disease, ultimately leading to better early detection and treatment options.

Hayward, CaliforniaHeadquarters

2018Year Founded

$225.7MTotal Funding

GRANTCompany Stage

Biotechnology, HealthcareIndustries

51-200Employees

Benefits

401(k) Company Match

401(k) Retirement Plan

Performance Bonus

Company Equity

Risks

Increased competition from Olink and SomaLogic may impact Alamar's market share.

Scaling production in Europe and APAC could strain resources and affect quality.

Regulatory hurdles in new regions may delay product launches and affect revenue.

Differentiation

Alamar's NULISA™ technology offers unprecedented sensitivity in protein detection.

The ARGO™ system automates high-throughput proteomics, reducing the need for technical expertise.

Alamar's focus on early disease detection sets it apart in the biotechnology field.

Upsides

ISO 13485:2016 certification boosts Alamar's credibility in the medical device industry.

European expansion with Milan headquarters enhances market reach and client service.

$10M investment accelerates Alzheimer's diagnostics development, strengthening Alamar's market position.

Land your dream remote job 3x faster with AI

Try Jobo Free